Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA4878952
Max Phase: Preclinical
Molecular Formula: C17H12N6O4
Molecular Weight: 364.32
Molecule Type: Unknown
Associated Items:
ID: ALA4878952
Max Phase: Preclinical
Molecular Formula: C17H12N6O4
Molecular Weight: 364.32
Molecule Type: Unknown
Associated Items:
Canonical SMILES: N#CNC(=N)c1ccc(C(=O)Oc2ccc(CC(=O)O)n3ncnc23)cc1
Standard InChI: InChI=1S/C17H12N6O4/c18-8-20-15(19)10-1-3-11(4-2-10)17(26)27-13-6-5-12(7-14(24)25)23-16(13)21-9-22-23/h1-6,9H,7H2,(H2,19,20)(H,24,25)
Standard InChI Key: WFPREWYLRKCXHF-UHFFFAOYSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Unknown | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 364.32 | Molecular Weight (Monoisotopic): 364.0920 | AlogP: 0.97 | #Rotatable Bonds: 5 |
Polar Surface Area: 153.46 | Molecular Species: ACID | HBA: 8 | HBD: 3 |
#RO5 Violations: 0 | HBA (Lipinski): 10 | HBD (Lipinski): 3 | #RO5 Violations (Lipinski): 0 |
CX Acidic pKa: 2.71 | CX Basic pKa: 4.17 | CX LogP: 0.12 | CX LogD: -1.92 |
Aromatic Rings: 3 | Heavy Atoms: 27 | QED Weighted: 0.20 | Np Likeness Score: -0.72 |
1. Zhang X, Zhu B, Sun W, Wang M, Albarazanji K, Ghosh B, Cummings M, Lenhard J, Leonard J, Macielag M, Lanter J.. (2021) Discovery of a novel series of guanidinebenzoates as gut-restricted enteropeptidase and trypsin dual inhibitors for the treatment of metabolic syndrome., 40 [PMID:33713780] [10.1016/j.bmcl.2021.127939] |
Source(1):